Samsara BioCapital’s Palvella Therapeutics PVLA Stock Holding History

Samsara BioCapital’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.79M	Sell	38,432 -66,385	-63%	-$6.92M	0.47%	21
2025 Q4	$11M	Sell	104,817 -104,817	-50%	-$8.94M	1.13%	14
2025 Q3	$13.1M	Sell	209,634 -130,109	-38%	-$5.8M	1.72%	11
2025 Q2	$7.66M	Sell	339,743 -339,743	-50%	-$7.97M	1.57%	10
2025 Q1	$19M	Hold	679,486	–	–	3.39%	6
2024 Q4	$8.15M	Buy	+679,486	New	+$10.7M	1.12%	16
2020 Q3	–	Sell	-20,253	Closed	-$5.2M	–	40
2020 Q2	$5.2M	Hold	20,253	–	–	1.67%	17
2020 Q1	$3.69M	Buy	20,253 +11,450	+130%	+$2.89M	2.13%	14
2019 Q4	$2.55M	Buy	+8,803	New	+$2.44M	1.22%	15

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samsara BioCapital's PVLA Position: Q1 2026 in Review

Samsara BioCapital reduced its Palvella Therapeutics (PVLA) stake by 63% in Q1 2026, selling an estimated $6.92M and leaving 38,432 shares worth $4.79M. The position accounts for 0.47% of the portfolio, ranked #21.

Samsara BioCapital first reported a position in PVLA in Q4 2019 and has held it in 9 quarters since. The position peaked at $19M in Q1 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Samsara BioCapital held 38,432 shares of Palvella Therapeutics worth $4.79M as of Q1 2026.
Samsara BioCapital sold 66,385 Palvella Therapeutics shares in Q1 2026, an estimated $6.92M.
Palvella Therapeutics made up 0.47% of Samsara BioCapital's portfolio in Q1 2026, its #21 holding.
Samsara BioCapital first reported a position in Palvella Therapeutics in Q4 2019 and has held it in 9 quarters since.
Samsara BioCapital's Palvella Therapeutics position peaked at $19M in Q1 2025.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.